Skip to main content

WST West Pharmaceutical Services, Inc.

Healthcare

steady quality, premium valuation.

Quality
Above avg
Valuation
Expensive
Key signals
Top-quintile 6-month momentum Filed revenue acceleration
362.01
362.01 Close (USD) Loading candles…

Is West Pharmaceutical Services, Inc. a buy? Fundamentals and valuation first

  • Quality is above average. Operating margin sits near the 74th percentile. TTM ROE is about 18.9%.

  • Valuation is expensive. TTM P/E is in the 90th percentile, above most peers.

  • Recent volatility is comparatively low. 60-day annualized volatility is in the 25th percentile. Average 20-day dollar volume is about $176.4M.

  • Signals are active now. Top-quintile 6-month momentum, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add West Pharmaceutical Services, Inc. to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 89.49152542372882%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

19 historical occurrences (since 2016-07-05)
Average forward return after Top-quintile 6-month momentum。20-day: Win 84.2%, Sample 19, Median +4.6%, Excess +1.54%, Beat mkt rate 63.2%；60-day: Win 61.1%, Sample 18, Median +3.15%, Excess +2.17%, Beat mkt rate 44.4%；120-day: Win 83.3%, Sample 18, Median +11.89%, Excess +8.22%, Beat mkt rate 55.6%

120 days after: historical avg +15.45%

20-day +3.85%
60-day +5.16%
120-day +15.45%
20-day
60-day
120-day
Win
84.2%
61.1%
83.3%
Sample
19
18
18
Median
+4.6%
+3.15%
+11.89%
Excess
+1.54%
+2.17%
+8.22%
Beat mkt rate
63.2%
44.4%
55.6%

Over 18 occurrences, 120-day forward avg gained 15.45%, beat the market by 8.22 pts; win rate 83.3%.

Filed revenue acceleration

Active · now 12.389350631799445%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

9 historical occurrences (since 2020-07-24)
Average forward return after Filed revenue acceleration。20-day: Win 88.9%, Sample 9, Median +3.36%, Excess +1.67%, Beat mkt rate 55.6%；60-day: Win 75%, Sample 8, Median +7.6%, Excess +1.45%, Beat mkt rate 50%；120-day: Win 57.1%, Sample 7, Median +12.36%, Excess +3.03%, Beat mkt rate 28.6%

120 days after: historical avg +11.49%

20-day +4.44%
60-day +4.52%
120-day +11.49%
20-day
60-day
120-day
Win
88.9%
75%
57.1%
Sample
9
8
7
Median
+3.36%
+7.6%
+12.36%
Excess
+1.67%
+1.45%
+3.03%
Beat mkt rate
55.6%
50%
28.6%

Over 7 occurrences, 120-day forward avg gained 11.49%, beat the market by 3.03 pts; win rate 57.1%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 341+32.4% +33.6% 99.1% +16.6%
20-40 230-13.2% -18.1% 17.8% -25.9%
40-60 You are here301-14.9% -14.2% 19.6% -28.1%
60-80 203-6.5% -18.5% 22.7% -20.4%
80-100 317+34% +47.3% 77.3% +13.9%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 46.29, placing it in the 50.9 own-history percentile, inside the 40-60 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+10.4%
Win rate 63.8% Excess +4.4%
210d
Now
-12.9%
Win rate 23.7% Excess -16.9%
270d
+17%
Win rate 72.5% Excess +4.9%
408d
60-day momentum down
+14.3%
Win rate 68.2% Excess +6.6%
381d
-7%
Win rate 20.3% Excess -12.5%
192d
+34.5%
Win rate 96.1% Excess +20%
51d

Currently in “Middle × 60-day momentum up”: across 270 historical days, 120-day forward avg declined 12.9%, win rate 23.7%, lagged the market by 16.9%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 98,524 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.12%, a 57.9% positive-return rate, and +2.77 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

24 times historically; 60-day forward avg +3.57%, win rate 54.2%, beating the market by +1.37 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

32 times historically; 60-day forward avg +3.71%, win rate 70%, beating the market by +0.47 pts on average.

Continue researching West Pharmaceutical Services, Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.